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Abstract 
Although the mechanisms of action of antipsychotics (APs) on neuronal 
function are well understood, very little is known about their effects on 
cells of the blood brain barrier (BBB); one function of which is to limit the 
access of these amphiphilic compounds to the central nervous system. To 
address this question we have investigated the cytological and functional 
effects of four APs:  chlorpromazine (CLP), haloperidol (HAL), risperidone 
(RIS) and clozapine CLZ), at concentrations typical of high therapeutic 
dosage on a human brain microvascular endothelial cell (HBMEC) model of 
the BBB. At ~10µM all four APs impaired the ability of HBMECs to reduce 
MTT which was followed by decreased Trypan blue exclusion and increased 
Lactate dehydrogenase release. These effects were associated with 
oxidative stress which was partly reversed by incubation in 10mM 
glutathione. At their EC50 concentrations for MTT reduction, all four APs 
disrupted cellular ultrastructure and morphology. HAL, CPZ and CLZ 
increased Caspase -3, -8 and -9 activity, chromatin condensation and 
fragmentation, data indicative of apoptosis. These events were associated 
with decreased transcytosis of Evans blue and increased transendothelial 
potential difference and electrical resistance of this BBB model. These 
findings suggest that at high therapeutic concentrations, CPZ and CLZ are 
likely to incur cytoxic effects and apoptosis of BBB endothelia with an 
impairment of barrier functionality. Such events may underlie the 
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aetiology of neuroleptic associated cerebral oedema and neuroleptic 
malignant syndrome.  
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1. Introduction 
Antipsychotics (APs) are widely prescribed to manage psychoses that 
occur with schizophrenia and bipolar disorder (Miyamoto et al., 2005). 
Initially thought to achieve their therapeutic outcome by blockade of 
central dopaminergic and serotonergic pathways, however, APs are now 
known to involve a wider range of receptor targets which may, at higher 
doses, impart advantageous as well as deleterious behavioural (Putten et 
al, 1991) and neurological sequelae (Wiklund et al., 2010). Indeed, it is 
well established that at high doses, members of the typical class of APs, 
such as the phenothiazine chlorpromazine (CPZ) can be cytotoxic for 
different types of cell in culture (Dwyer et al., 2003) as well as inhibiting 
the proliferation of both normal and cancer cells (Nordenberg at al 1999). 
Whereas, other typical antipsychotics, which have different chemical 
structures, such as haloperidol (HAL) a butyrophenone, still have a similar 
clinical outcome as CPZ but do not, however, always have the same 
neurotoxic effects that are associated with high dosages of phenothiazines 
(Munyon et al.,1987; Galili-Mosberg et al., 2000).  
The mechanisms that underlie AP neurotoxicity remain unclear. They may 
be related to their direct actions as ligands on dopaminergic and 
serotonergic receptors (McGrath and Neifeld, 1985), or indeed other 
receptor classes such as sigma receptors (Vilner et al., 1995). Their 
neurotoxicity may result from disruptive actions on mitochondria and 
oxidative respiration (Dudani and Gupta, 1987) or occur via disruption of 
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cellular cholesterol metabolism (Dujovne and Zimmerman, 1969; Wiklund 
et al., 2010). However, any in-vivo appreciation of the neurological 
functional sequelae of AP usage, whether with normal or overdosage is 
confounded by the fact that the access of these drugs to the CNS and 
their associated pharmacokinetics, are subject to the transport properties 
of the blood brain barrier (BBB). 
The BBB controls the transport of metabolites, drugs and chemicals 
between the blood and brain compartments, in doing so it acts to both 
protect, but also maintain, the interstitial environment of the CNS (Abbott 
2013, Abbott et al 2010; Wilhem et al 2011).  Anatomically, the structure 
of the BBB comprises of a monolayer of brain micro-vascular endothelial 
cells joined by tight and adherent junctions (Weiss et al., 2009; Abbott et 
al 2010). This physical arrangement ensures that the endothelial cells act 
to restrict the movement of microscopic particles (e.g. bacteria) and 
hydrophilic molecules into the cerebrospinal fluid (CSF) (Bernas et al., 
2010; Abbott 2013, Abbott et al 2010). Once this barrier is breached, the 
CNS is exposed to potential insult by hazardous solutes and pathogens 
circulating in the blood (Abbott et al 2010). In fact the BBB is functionally 
predisposed to prevent the entry of amphiphilic compounds such as APs 
into the CNS, which raises the question as to the mechanism by which 
these drugs actually gain access to the CNS and affect their therapeutic 
action (Abbott 2013, Abbott et al 2010; Wilhem et al 2011). This is a 
particularly pertinent problem since endothelial cells of the BBB possess 
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members of the ABC transporter family such as P-glycoprotein (Cordon-
Cardo et al., 1989; Abbott et al 2010) whose predominant function is to 
actively pump amphiphilic compounds out of cells. One possible 
mechanism by which APs accumulate in the CNS is that these drugs 
inhibit, or are not substrates, for P-glycoprotein of the BBB endothelial 
cells. Alternatively the membrane permeability of the APs may be 
sufficiently high such that their passive influx exceeds the capacity of P-
glycoprotein to extrude them the . Another further mechanism by which 
APs may gain access to the CNS is that the drugs themselves are cytotoxic 
to the cells of the BBB with the resultant impairment in the barrier 
function allowing them access to the CNS. 
It is unknown is to what extent that AP, especially at dosages at the 
higher end of their therapeutic window, affect the function of cells of the 
BBB, a phenomena that will have consequences for transport of these 
drugs across the BBB, their associated pharmacokinetics, as well as the 
overall effect of APs on CNS function and their clinical outcome. APs, at 
concentrations similar to those measured in the serum of highly dosed 
patients, are already established to induce gross permeability changes in 
the BBB; for example its permeability to FeCl3, mannitol and inulin are all 
enhanced by acute administration of 5µM CPZ (Pardridge et al., 1973; 
Ben-Shachar et al., 1994), a phenomenon indicative of a BBB breach at a 
drug concentration similar to that occasionally measured in human serum 
(3µM, 1000ng/ml; Van Putten et al, 1991), and. 
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Since it is possible to isolate and culture the different cell types that 
constitute the BBB (Bernas et al., 2010) the primary aim of this study was 
to investigate the cellular and functional effects of two typical APs (CPZ 
and HAL) and two atypical APs: risperidone (RIS) and clozapine (CLZ), at 
the higher end of therapeutic levels, as well as those expected with over 
dosage, on a model system of the BBB. In particular, we wished to 
determine to what extent these drugs affect cell viability, programmed cell 
death, barrier permeability and to investigate putative mechanisms behind 
these processes. 
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2. RESULTS 
We first investigated the concentration dependence for the effect of two 
typical (CPZ and HAL) and two atypical (RIS and CLZ) APs on the viability 
of human brain microvascular endothelial cells (HBMECs).  
2.1 Antipsychotics impair HBME cell viability 
Figure 1 show the relationships between drug concentrations and 
reduction of MTT and exclusion of trypan blue for HBMECs for 4 different 
time points (4hrs, 24hrs, 48hrs and 72hrs). At concentrations of AP at 10 
µM or less, all the drugs significantly inhibited the ability of the cell 
population to reduce MTT relative to control (p<0.001, ANOVA). However, 
even at concentrations in excess of 0.3-1mM and with extended 
incubation times of 72hrs none of the drugs abolished MTT reduction, with 
~ 20-30% of the cell population apparently resistant to the action of the 
APs. The inhibitory effects of the APs on the cells ability to reduce MTT 
were mirrored by a decreased ability of the cells to exclude trypan blue; 
data which indicates that a loss of plasma-membrane integrity of the cells 
is associated with their redox capability. For both the MTT and trypan blue 
exclusion assays, the concentration-effect relationships for HAL and RIS 
were best described by a monophasic relationship (equation 1, Fraction = 
0). For CPZ and CLZ their concentration-effect relationships on MTT were 
best described by a biphasic relationship (equation 1) with the IC50 for the 
highest affinity components given in Figure 2. The fraction of the high 
affinity components were 0.29 (0.14 to 0.44, 95% CI) and 0.34 (0.27 to 
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0.41, 95% CI) for CPZ and CLZ respectively. A monophasic equation (as 
compared to a biphasic using the F-test) best described the relationship 
between the concentrations of these drugs and the exclusion of trypan 
blue. Over the 72hr incubation period neither the drugs nor vehicle control 
produced a significant change in total cell count: cells excluding trypan 
blue + cells containing trypan blue. This data inundates that the 
proliferation rate of the cells was slow enough as not to be affected by the 
time courses of the experimental paradigms employed. 
For both RIS and HAL, a significant release of LDH (ANOVA) occurred at all 
concentrations tested, with a greater release at higher concentrations 
(data not shown). However, even after 24hrs incubation with either drug 
at 1mM, only around 60% of the cell population released LDH; data again 
indicative of a population of cells resistant to the cytotoxic effects of these 
drugs. The concentration-effect relationship between either RIS or HAL 
and the release of LDH was readily described by the monophasic form of 
equation 1 with the IC50 given in Figure 2. CPZ and CLZ produced similar 
effects on the release of LDH, with the data best described by  the 
monophasic form of equation 1 with the IC50s given in Figure 2.  
Figure 2 clearly demonstrates that both CLZ and CPZ develop a greater 
effect and potency with the MTT assay than on trypan blue exclusion at 
prolonged exposure times; an observation that suggests that a decrease 
in cellular redox status precedes the loss of cell integrity.  
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To further clarify the temporal effects of the APs, the relationships 
between the percentage viability with 10µM of drug were plotted against 
the time of exposure (Fig. 3). For all four APs tested, both MTT reduction 
and TB were significantly and negatively correlated with incubation time 
for a fixed drug concentration (r<-0.95, p<0.05 for all cases; Pearson 
one-tailed). The greatest drug effect was always demonstrated with the 
MTT assay (p<0.001, for each drug tested ANOVA); data again suggestive 
that a decrease in cellular redox status precedes the loss of cell plasma 
membrane integrity. 
2.2 Antipsychotics condense chromatin 
Cell visualised with transmission electron microscopy (TEM) revealed that 
vehicle treated cells appeared normal (Fig. 4), whilst cells treated with 
antipsychotics had degraded organelles, vacuolated cytoplasm, nuclear 
breakdown, increased electron density and chromatin condensation; 
observations consistent with apoptosis. Qualitatively, these apoptotic 
effects appeared to be the most prominent in CPZ and CLZ treated cells, 
but least in those treated with RIS and HAL. The induction of apoptosis by 
the APs was supported by the observation of heterogeneous DAPI staining 
of the nuclei.  After 24hrs incubation at their EC50s for viability, the APs 
led to ~50% of the nuclei to become heterogeneously stained: 50±2%, 
51±0.3%, 46±2% and 46±0.5% for CPZ, HAL, RIS and CLZ respectively.  
2.3 Antipsychotics-induce DNA breakage 
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The TM and TD components of the Comet assay from cells treated with 
vehicle or APs are shown in Figure 5. Although there was no significant 
effect for any drug on the TM (ANOVA), the TD component was 
significantly increased by 7.6% with CPZ (p<0.001; ANOVA) and 3.2% 
with CLZ (p<0.01; ANOVA). Although we observed Gamma-Histone H2AX 
staining within DAPI labelled nuclei with all treatments the actual amount 
of staining, quantified by the number of immunofluorescent spots per cell, 
was almost identical between the APs and the vehicle control (p=0.112, 
Chi2 test; data not shown).  
2.4 Antipsychotics and the cell cycle 
There was no discernible effect of the APs on the number of cells in the 
G0/G1 phase or the G2/G1 ratio of the cell cycle. 
2.5 Antipsychotics activates Caspase-3, -8 and -9 
Figure 6 shows, with the exception of RIS, the APs caused a significant 
increase in the activity of Caspases-3, -8 and -9 relative to the vehicle 
control (ANOVA).  
2.6 Antipsychotics impair the transport properties of confluent 
monolayers. 
When applied for 72hrs at their EC50 concentration for viability, both CLZ 
and CPZ greatly enhanced the permeability of Evans blue across HBMEC 
monolayers (Fig. 7). In fact, an enhanced flux of Evans blue was observed 
even after 2hr incubation with the drugs at these concentrations. 
Microscopic inspection of the endothelia monolayers revealed widespread 
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disruption of monolayer structure and continuity, data which suggests 
these drug concentrations are too aggressive for the BBB to maintain 
functionality. In response to this situation, the experiments were 
repeated, but with the monolayers incubated at half the EC50 for each 
respective AP. Under these conditions, the permeation of Evans blue after 
72hr incubation with AP was significantly decreased by both CPZ and CLZ 
(p<0.01, p<0.001 respectively; Kruskal Wallis Dunns multiple comparison 
test to control) but not by RIS or HAL. Figure 7 shows that for both APs 
and vehicle, both the TEER and TEPD significantly increased in magnitude 
with incubation time (p<0.05 for TEER; p<0.01 for TEPD; Spearman Rank 
correlation for all cases). Moreover all four APs significantly increased both 
TEER (p<0.01 for all cases) and TEPD (p<0.01 for all cases with the 
exception of CPZ p>0.05; Figure 7) relative to the values measured for 
vehicle (2-way ANOVA, Dunnett's multiple comparison test in each 
instance).  
2.7 Antipsychotics cause oxidative stress. 
Figure 8 illustrates that, with the exception of RIS, the APs, along with 
antimycin A the positive control, at their lowest concentration tested 
(<10µM) all significantly (p<0.001, ANOVA) increased oxidative damage, 
indicative of ROS generation, relative to that produced with the vehicle 
control. At their EC50s for cell viability, all four APs significantly increased 
ROS generation relative to vehicle control (p<0.001, ANOVA). To 
determine if the production of ROS and the resultant oxidative damage 
was responsible in part for the decrease in viability observed on exposure 
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of the HBMECs to the APs, cells were co-incubated with 10mM glutathione 
(GSH); a reductant known to protect against oxidative stress and its 
associated cellular damage. With the exception of CLZ, 10mM glutathione 
significantly (p<0.05 in all cases, Unpaired t-test), but only partially, 
reversed the decrease in MTT reduction produced by the APs at both the 
lowest concentration tested and their EC50 concentration for viability. 
However, in no case was 100% viability restored. 10mM glutathione also 
reversed the DNA damage produced by CLZ at its EC50 for viability as 
indicated by the Comet assay (Fig 5). 
3. DISCUSSION  
The primary aim of this study was to investigate the cellular and 
functional effects of four antipsychotics (APs): two typical, CPZ and HAL, 
and two atypical, RIS and CLZ, on a HBMEC model of the BBB, in 
particular at concentrations similar to those seen with therapeutic over 
dosage in man as well as those commonly used in animal models. At 
concentrations of ~10µM and greater, all four drugs were found to 
adversely affect HBMEC function, with CPZ and CLZ the most potent, HAL 
and RIS lesser so. All four drugs impaired the ability of HBMECs to reduce 
MTT, an effect paralleled by a loss of plasma membrane integrity with 
increased uptake of trypan blue and leak of lactate dehydrogenase. At 
their EC50 concentrations for these effects, all four APs disrupted cellular 
ultrastructure and morphology. However, the same concentrations of 
drugs did not affect DNA breakage (except CPZ) as indicated by the alkali 
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Comet assay, nor did they affect Gamma-Histone H2AX staining or the cell 
cycle. HAL, CPZ and CLZ, but not RIS, did increase the activity of 
Caspases -3, -8 and -9 as well as promoting chromatin condensation and 
fragmentation, data indicative of apoptosis. These cytotoxic effects were 
associated with changes in the transendothelial permeability and electrical 
properties of a BBB model. The cytotoxic effects of these drugs were in 
part mediated by oxidative stress since their action was partially blocked 
with glutathione, a reductant well established to protect against oxidative 
stress associated cytoxicity (Slater et al 1995). 
Mechanisms of cytotoxicity 
Phospholipidosis and bioenergetic impairment are two established 
mechanisms by which antipsychotics induce cytotoxicity. Amphiphilic 
compounds such as antipsychotics can promote phospholipidosis 
(Halliwell, 1997), as well as interact directly with cell membrane sterols 
(Dujovne and Zimmerman, 1969; Erik et al., 2010) either of which could 
induce the cytotoxic changes we observed.  
It is also well-established that antipsychotics can impair cellular 
bioenergetics (Dwyer et al., 2005). These effects need not be secondary 
to that of phospholipidosis; since, CPZ, HAL, RIS and CLZ are known to 
affect mitochondrial function by an inhibition of Complex I of the electron 
transport chain, with IC50’s of ~35µM for CPZ and HAL, ~65 µM for RIS 
and >200µM for CLZ in isolated mitochondrial preparations (Burkhardt et 
al., 1993; Modica-Napolitano et al., 2003). CPZ can also impair succinate-
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cytochrome C reductase activity as well as acting as a mitochondrial 
uncoupler (Modica-Napolitano et al., 2003). Indeed the inhibition of 
Complex I within neurons of the cortex by neuroleptics has previously 
been proposed to partly explain the extrapyramidal symptoms seen with 
this class of drugs (Maurer & Möller, 1997). 
A consequence of mitochondrial function disruption is the induction of 
apoptosis. The fact that in our study the APs led to nuclei heterogeneously 
stained with DAPI, chromatin condensation, as well as degraded 
organelles and vacuolated cytoplasm, supports an apoptotic rather than 
necrotic mechanism of AP cytotoxicity. An idea also supported by the 
ability of HAL, CPZ and CLZ, but not RIS,  to activate the caspases -3, -8 
and -9; enzymes whose activation is strongly  associated with the 
apoptotic cascade (Ola et al., 2011). RIS may induce apoptosis via a non-
caspase pathway. 
The observation that the APs always had greater effect on MTT reduction 
than on TBE; suggests the cytotoxic effect is initially precipitated by 
impairment in the cellular redox status. This idea is consistent with a 
mitochondrial target of the APs and is supported  by the following 
explanation of the conundrum as to why ~30-40% of any cell population 
may be explained by the fact that cells at certain stages of the cell cycle 
(Finkel and Hwang, 2009) are endowed with different metabolic profiles: 
during the G1 phase, energy production occurs predominantly via 
mitochondrial aerobic respiration, whereas during S and G2 phases it 
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occurs predominantly by aerobic glycolysis (Schieke et al., 2008). Our cell 
cycle analyses demonstrated that the populations of HBMECs we used 
were not fixed at any particular stage of cell cycle but had cells in GO/G1, 
S and G2. Since Complex I of the mitochondrial electron transport chain is 
suggested to a major target for the APs we used, this notion implies that 
cells in the S1 and G2 phases (~40% present study) whose metabolic flux 
is predominantly glycolytic would be resilient to the cytotoxic effects of 
these drugs, where as those in the G1\G0 phase of cell cycle (~60% 
present study) would be prone. Since these percentages of cell cycle 
phase are almost identical to the respective proportion of cells resilient 
(~40%) or adversely affected (~60%) by the antipsychotics, is strong 
evidence in support of the cell cycle phase and its associated bioenergetic 
state affecting the cytotoxicity of antipsychotics in this HBMEC of the BBB. 
Comparative potency of the antipsychotics 
After 72hr exposure, CPZ had the most potent affect of the four APs on 
MTT reduction, with an IC50 of <1µM (~1µM at 48hr) compared to 2µM for 
CLZ, 48µM for HAL and 56µM for RIS.  This data implies that, for CPZ and 
CLZ at least, cytoxic effects of the BBB may occur with concentrations of 
these AP at the higher end of their clinical therapeutic window: 300 ng/ml 
(1µM) for CPZ and 700 ng/ml (2µM) for CLZ. The fact that the ability of 
both CLZ and CPZ to inhibit MTT reduction was biphasic in nature suggests 
that at least two sites of action exist for these two drugs. Interestingly the 
IC50s for the low affinity sites of these APs at 50µM and 200µM for CPZ 
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and CLZ respectively are similar in magnitude to those estimated for HAL 
and RIS; a finding which suggests that all four of these APs may share a 
common, as yet undefined, low affinity target of action. When fitting the 
biphasic relationship between MTT and the concentration of CPZ or CLZ it 
was assumed that the fractional contribution of this component was 
constant and it was the affinity, IC50, that changed with time. However, it 
is more likely that the IC50 for the high affinity component is actually 
constant and it is the fractional contribution of this component that 
increased with time; an idea consistent with either intracellular 
accumulation of the drug or\and the aggregation over time of its 
molecular action. The observation that neither the loss of LDH or exclusion 
of trypan blue did not have a high affinity component unlike MTT for either 
CPZ or CLZ strongly suggests that the temporal decrease in MTT observed 
with these two APs at low concentrations reflects a gradual impairment of 
redox potential with drug exposure as demonstrated in figure 3 for these 
two drugs. Whereas for HAL and RIS, who lack this high affinity 
component, a higher concentration of drug is needed to do induce 
cytotoxicity via the low affinity site which just happens to be just happens 
to be the associated with a more rapid onset of action. The fact that 
trypan blue exclusion, an indicator of cellular integrity, lags behind the 
decrease in MTT by between 12 to 24 hours (fig.3) suggests that this is 
the period of time it takes to complete the apoptotic pathway which 
culminates in cell death and trypan blue uptake. Indeed similar length 
delays between cytotoxic induction and completion of apoptosis has been 
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described in other cellular systems e.g. 18hr for MPP + induced apoptosis 
in neuroblastoma (Fall & Bennett 1999). 
A similar ranked order of cytotoxic potency for these APs is reported for 
the phaemocytochroma cell line, PC12 after 48hr exposure; with IC50s of 
60 µM and 110µM for CPZ and CLZ respectively, and ~200µM for both RIS 
and HAL (Dwyer et al., 2003). In endothelial cells of the human umbilical 
vein (HUVECs) after 72hr exposure, CPZ was shown to be slightly less 
cytotoxic with an IC50 of 25µM, whereas HAL had no effect up to 400 µM 
(Wiklund et al., 2010).  It thus appears that HBMECs are exquisitely 
sensitive to CLZ and CPZ compared to HAL and RIS. Interestingly, the IC50 
values for the cytotoxic effects of CPZ is similar to the value reported for 
its direct inhibitory effect on the activity of Complex I in isolated rat brain 
mitochondria: IC50 of <5µM (Rosenfeld et al., 2011). Together, this 
evidence suggests that for CPZ to achieve a potency in HBMECs similar to 
that observed for its inhibition of Complex I in isolated mitochondria the 
drug must have easy access to the cytosol. Moreover, a predominantly 
mitochondrial effect of these drugs explains why a decrease in redox 
status, as monitored by the MTT assay, appears to be the primary event 
in the cytotoxic cascade described here. 
The generation of ROS with the production of oxidative stress and damage 
is known to occur with agents that inhibit mitochondrial electron transport. 
This fact is exemplified by our observation with Antimycin A which blocks 
complex II of the mitochondrial electron transport chain; an action well 
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documented to lead to ROS production. Our findings support this notion 
and indeed corroborate previous literature that demonstrates increased 
oxidative stress by APs such as HAL and CPZ in the CNS in-vivo (Reinke et 
al 2004). Elevated ROS can act as a trigger for apoptosis (Slater et al 
1995) as well as having direct cytotoxic effects on a variety of cellular 
proteins and processes. Our observation that exogenously supplied 
glutathione partly alleviates the decrease in MTT observed with the APs, 
as well as preventing DNA breakage as indicated by the Comet assay, is 
strong evidence for a role for oxidative stress in the mechanism of AP 
cytotoxicity. It is of note that only CPZ affected DNA breakage, an 
observation that presumably relates to the fact that it was the most 
potent drug studied. 
One question is to how these drugs accumulate to high enough 
concentrations to be mitochondrial poisons since endothelial cells of the 
BBB possess members of the ABC transporter family such as P-
glycoprotein (Cordon-Cardo et al., 1989): proteins which act to pump 
amphiphilic compounds, like APs out of the cell and in the case of 
endothelial cells, out across the BBB (Hembury et al., 2008; Hemmelmann 
et al., 2012). Our data suggests that the drugs we used are either not 
transported by P-glycoprotein or they inhibit its activity. Alternatively, 
these APs may possess passive membrane permeability so high such that 
their rate of influx is larger than, and overwhelms that, of the P-
glycoprotein efflux pathway; a scenario already demonstrated for CPZ in 
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BBB models (Seelig, 2007). Although these APs at ~30µM can stimulate 
the ATPase activity of P-glycoprotein and are perhaps substrates for 
transportation (Boulton et al., 2002), the observation that at similar 
concentrations they actually inhibit the ability of this protein to extrude 
the amphiphilic molecule, RH123 from cells (Wang et al., 2006) strongly 
suggest APs are in fact inhibitors of this particular ABC transporter. Such 
an action will contribute to their relatively high potency of cytotoxicity due 
to the inability of the cell to extrude them and prevent their intracellular 
accumulation. 
Another factor of consideration in the cellular dynamics of these drugs is 
that they all have ionisation constants (pKa’s) > 7.4 (Lombardo et al., 
2004) which means they will accumulate in the relatively acidic 
environment of the cytosol. Finally, all four drugs possess halogen 
moieties within their molecular structures, a structural feature that 
enhances their membrane permeability and potency (Gerebzoff et al 
2004). 
At their EC50’s for cell viability we have shown that the antipsychotics are 
capable of severely disrupting cell integrity and function of endothelial 
cells of the BBB. Even at concentrations within the upper range of 
therapeutic doses, let alone overdose, a significant decrease in cell 
viability was noted; affects exacerbated for CLZ and CPZ after an 
extended period of incubation. The in-vivo consequences are numerous; 
at excessively high concentrations of APs subsequent damage to the BBB 
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would make it leaky, not just to blood solutes and components with 
ensuing extravasation (Pardridge et al., 1973; Ben-Schachar et al., 1994), 
but also to the APs themselves with the various pathological consequences 
this implies. Indeed, we have demonstrated that prolonged exposure at 
high drug concentrations induce cytoxic actions on the HMBECs of the BBB 
with a concomitant loss of its integrity and a subsequent inability to act as 
a physical barrier to the passage of the drugs into the brain. Whereas at 
the lower doses of APs we tested, more akin to those seen at the higher 
therapeutically-relevant serum concentrations in man: 0.2-1µM for 
CPZ,.15-2µM for CLZ, we saw an associated decrease in transepithelial 
transport and enhanced transepithelial electrical resistance Since the 
transcellular flux of Evans blue occurs via an energy-dependent 
transcytosic process (Abbott 2013), its decrease with the lower doses of 
CLZ and CPZ is consistent with the ability of these drugs to decrease the 
energy state of the cells, as indicated by the MTT assay.  
Regardless of whether the APs produce a breakdown in the endothelium of 
the BBB, impair their bioenergetics or/and wreak oxidative stress damage, 
any of these phenomena may contribute to the associated 
neuropathologies observed with long term AP therapy such as neuroleptic 
associated cerebral oedema (Jellinger 1977) and neuroleptic malignant 
syndrome (Karagianis et al 1999). Since apoptosis was observed with 
even the lowest concentrations of drug employed at the shortest 
incubation time suggest that a bolus of AP in-vivo may be sufficient to 
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illicit catastrophic damage to the BBB. Whether over dosage with the APs 
used within this study, or elevated levels outside their therapeutic window 
affect the endothelial integrity of other microvasculature within the body 
with its concomittant sequelue are unknown.  
4. Experimental Procedure 
Chemical and reagents. 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl 
tetrazolium bromide (MTT) and DAPI were purchased from Promega 
(Corp., Madison, Wisconsin, USA). CLZ was purchased from Abcam 
(Cambridge, MA, USA). All other reagents, including CPZ, HAL and RIS 
were purchased from Sigma-Aldrich (Poole, UK) unless stated otherwise. 
All stock solutions of drugs were made in ethanol (vehicle). 
4.1 Cells and tissue culture conditions 
For this study we used primary human brain microvascular endothelial 
cells (HBMECs), a fundamental element of the BBB. Cells were used from 
passage 21-23 and were grown and maintained as previously described 
(Elsheikha et al., 2013). When confluent, our HBMECs demonstrated an 
endothelial morphology with features all typical of a functional 
endothelium constructed from this cell type (Wong et al., 2004; Colgan et 
al., 2008; Allen and Bayraktutan, 2009; Wilheml et al 2011): 
transendothelial electrical resistances (TEER) of ~100Ωcm-2; 
transendothelial potential differences (TEPD) of ~1mV; and an 
impermeability of albumin conjugated Evans blue. The fact that a TEPD 
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was observed supports the idea that our monolayers were a homogenous 
tight barrier with the absence of any gaps to produce an electrical 
leakage, since these would dissipate the TEPD; even though the TEER 
appear to be relatively low to those measured in other cellular (200Ωcm-2; 
Wilhelm et al 2010) and ex-vivo (>1000Ωcm-2; Abbot et al 2010) models 
of the BBB. Furthermore, the observation the monolayers significantly 
decreased the passive flux of Evans blue across the transwell also argues 
for a continuum of tight junctions between cells that limits paracellular 
flux.  
4.2 Cytotoxicity assays:  
Fluorescent microscopy was conducted with a Leica DM5000 (Leica, B 
Wetzlar, Germany) with images collected and processed with a Leica 
DFC420 camera and Leica application suite v3.8 software. Since APs have 
long half-lives, especially in the cases of overdose where their metabolism 
is changed from 0th to 1st order kinetics (Ereshefsky, 1999), we 
performed experiments at four different time points to mimic this: 4hrs, 
24hrs, 48hrs and 72hrs post treatment. These longer time periods of 
incubation were further warranted due to the time-dependence of AP 
cytotoxicity, often taking at least 48hrs to achieve a maximum effect (Erik 
et al., 2010). The lowest concentrations of CPZ and CLZ used in our 
experiments are near to the top end of therapeutic serum levels for CPZ 
and CLZ: 0.2-1µM (40-300 ng/ml) and 1-2µM (300-700 ng/ml) 
respectively, and are similar to those measured in overdosed individuals: 
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~3µM for CPZ (~1000ng/ml; Van Putten et al 1991) and ~5µM for CLZ 
(~1500ng/mL; Chang et al 1997). For HAL and RIS the lowest 
concentrations of drugs used were about 70-80 times therapeutic serum 
levels: 5-135nM (2-50ng/ml) for HAL and 50-160nM (20-65 ng/ml) for 
RIS, although the lowest values we used in the present study are similar 
to those measured in highly/over dosed individuals: ~ 0.7µM for HAL 
(~270 ng/ml; Chang et al 1994) and  for RIS ~0.5-0.8µM (~220 to 320 
ng/mL ng/ml; Titier et al 2003, Nishikage et al 2002). We used these 
higher concentrations to accelerate and evoke detectable effects of the 
APs within the time frame of cell division as not to be confounded by 
affects on cell proliferation. Furthermore, the concentrations used allowed 
us to mimic overdose scenarios that are clinically experienced.  
4.2.1 MTT assay 
The MTT assay relies on cellular reduction of the MTT substrate to produce 
a blue formazan product. As such it is a facile indicator of cell viability that 
results from the product of cell number and redox status. For this assay 
we followed the manufacturer protocol (CellTiter 96 Non-Radioactive Cell 
Proliferation Assay; Promega, UK). Briefly, cells were seeded at 1x104 
cells per well in 96-well plastic plates (Nunc) and incubated overnight at 
37°C under humidified 5% CO2 conditions. To assess chronic effects cells 
were then incubated for a 4, 24, 48 or 72hrs in the presence of drug or its 
vehicle. The original drug and vehicle measurements were corrected via 
subtraction of a blank (media with MTT reagents but without cells). The 
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MTT absorbance value is expressed as a percent of the vehicle control 
(defined as 100%). Each experiment was performed in triplicate, where n 
represents the number of experiments (triplicates) performed. 
4.2.2 Lactate dehydrogenase assay 
Plates for this assay were prepared as for MTT, but with lysis by 2% Triton 
X-100 the positive control. All measurements were corrected via 
subtraction of a blank (media with reagents but without cells). Leakage of 
LDH was calculated as a percentage of the Triton X-100 positive control. 
Since LDH release was unaffected by vehicle we did not correct for it.  Due 
to degradation of LDH in the media over extended incubation times only 2 
time points (4 and 24hrs) were assayed for its release. Each experiment 
was done in triplicate, where n represents the total number of 
experiments (triplicates) performed. 
4.2.3 Trypan blue exclusion assay 
To aid comparison with the MTT assay and determine the number of viable 
cells we harvested both attached and floating cells for this assay. As the 
vehicle did not affect the TBE assay we have not corrected for it.  Results 
are expressed as % viability compared to control. Each experiment was 
done in triplicate per treatment, where n represents the number of 
experiments (triplicates) performed. 
4.3 Genotoxicity and apoptotic assays 
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To investigate nuclear/DNA toxic effects of the APs a variety of techniques 
were used. For these protocols, drug treatment was achieved by 
incubation of the cells for 24hrs at the EC50 concentration obtained from 
the respective MTT assay for the APs tested: CPZ, 78µM; HAL, 330µM; 
RIS, 300µM and CLZ, 153µM (see Figs. 1 & 2). For vehicle control, the 
same volume of ethanol was added as used for drug.  
4.3.1 Caspase Assay 
To determine the pathway(s) by which APs, may induces apoptosis we 
evaluated the activities of caspases 3, 8 and 9 after treatment with the 
APs. These were determined using a BD ApoAlert caspase fluorescent 
assay kits (Clontech Laboratories, Palo Alto, CA).  
4.3.2 Ultrastuctural damage 
Nuclear changes indicative of apoptosis were assessed by staining with 
DAPI and measuring the proportion of cells with chromatin condensation 
and nuclear fragmentation. Nuclei were considered to have a healthy 
phenotype when their fluorescence was homogeneously bright, whereas 
apoptotic nuclei were identified by condensed chromatin at their periphery 
or a fragmented morphology. For analysis, at least 300 cells from 10 
different fields of each treatment were counted and scored blind.  Each 
treatment was repeated at least 3 times. The number of the homogenous 
(healthy) nuclei was quantified as a percentage of the total nuclei for each 
27 
 
experiment. Transmission Electron Microscopy (TEM) was also used to 
study the structural integrity of cell nuclei.  
4.3.3 Comet assay 
The alkaline Comet assay is a sensitive method that can detect both single 
and double stranded DNA breaks. Its “tail” parameters are the most 
frequently used to describes DNA damage, with the tail moment (TM) and  
tail DNA (TD) considered the most accurate markers of such damage (De 
Boeck et al., 2000). After treatment with APs, cells were harvested in ice-
cold PBS and exposed to 30% ethanol. The infranatant was mixed with 
agarose and plated onto slides. After lysis, the samples underwent 
electrophoresis (30 minutes at 300 mA) and stained with propidium iodide 
(1mg/ml). Cells were imaged by fluorescent microscopy at 546nm 
excitation and 640nm emission. Images were analysed by Comet score IV 
software (Perspective Instruments, UK).  
4.3.4 Gamma-Histone H2AX  
Gamma-Histone H2AX (γH2AX) is another marker for double stranded 
DNA breaks (Lowndes and Toh, 2005). For γH2AX staining, cells were 
grown on glass coverslips for 24 hrs and then treated with APs. 
Inmunohistochemistry was performed with a Anti-H2AX mouse primary 
antibody (phospho-Ser139, #05-636; Millipore, Billerica, MA) and an 
AlexaFluor 594nM tagged fluorescent secondary antibody (Invitrogen, 
Eugene, OR). Samples were examined with fluorescent microscopy using 
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dual excitation and emission filter pairs of 360nm and 470nm for DAPI, 
and 546nm and 640nm for H2AX. A minimum of 100 nuclei per sample 
were examined and the number of γH2AX foci per nuclei counted. 
4.3.5 Cell cycle analysis 
Cells were cultured in T25 flasks for 24 hrs and then treated. Both floating 
and adherent cells were harvested and pelleted by centrifugation. DNA 
content stained by propidium iodide was analysed by FACScan with 
495nm excitation and 600nm emission (Beckman Coulter, High Wycombe, 
UK). Data were analysed with Weasel software version 2.7.4 (Walter & 
Eliza Analysis Software). Doublets and cellular aggregates are a common 
problem of DNA analysis, where summation of the individual G1-phase 
DNA contents is often recorded as a single event which leads to 
overestimation of the G2/M population (Nunez, 2001). To overcome this 
problem we only selected the area that contained single cells. These 
experiments were repeated in triplicate. 
4.4 Measurement of reactive oxygen species 
We used the 3',7'-dichlorodihydrofluorescein diacetate (DCFDA) assay to 
detect products of oxidative stress that result from the presence of 
reactive oxygen species (ROS). Cells were cultured in 96-well plates and 
treated for 24hrs with APs at either at its EC50 for viability or the lowest 
concentration tested. Cells were then washed with PBS and incubated with 
100μM DCFDA in Hanks for 45 minutes at 37°C. Ethanol was used for 
29 
 
vehicle control, Antimycin A (10µM for 30 minutes) as the positive control 
and wells with non-stained cells were used as blank. Cells were then 
washed with PBS and their emitted fluorescence at 535nm measured with 
485nm excitation. The drug and vehicle measurements were corrected via 
subtraction of the blank. The oxidative products due to thepresence of 
ROS are expressed as a percent of the vehicle control (defined as 100%). 
Each experiment was performed in triplicate, where n represents the 
number of experiments (triplicates) performed. 
4.5 Functional assays 
To assess the functional outcome of the antipsychotics and also to confirm 
that our HBMEC cultures suitably modelled the transport properties of the 
BBB endothelium, we utilized three assays of endothelial function: 
transcellular transport of Evans blue, transendothelial electrical resistance 
(TEER) and transendothelial potential difference (TEPD). For these studies, 
cells were grown to confluence on semi permeable membrane 24-well 
inserts (area 0.6 cm2; Millicell, Millipore Corporation). Cells were incubated 
with APs for 72hrs at either the full or half of the respective MTT EC50 
concentration. For controls, wells with confluent cells were incubated with 
either vehicle alone or with just media with no additions. To assess the 
transcellular permeability, Evans blue (0.05 mg ml-1) labelled albumin 
(4%) was added to the culture media in the well insert. The passage of 
labelled albumin across the monolayer was determined by the increase in 
absorbance at 620 nm of the infranatent after 3 hours. 
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To measure the TEER and TEPD of the endothelial monolayer, we used a 
WPI EVOM resistance meter (WPI, UK). This was prepared and calibrated 
in accord with the manufacturer’s instructions. Controls with wells but 
without cells did not restrict the movement of Evans Blue nor did they 
possess a TEPD. However, blank wells do have a TEER which is in series 
with that of the monolayer, this was corrected for by subtraction. 
4.6 Statistical analysis 
The D’Agostino-Pearson omnibus normality test was always sused to 
check if data was Gaussian distributed. For multiple comparisons on 
Gaussian distributed data, one way ANOVA test was used with either 
Tukey’s multiple comparisons or Dunnett’s multiple comparisons post-
tests, whereas for non-normal data Kruskall Wallis test with Dunnett’s 
multiple comparisons post-test was used;  for counts, Chi2 was used. 
Either Pearson r or Spearman Rank was used to correlate variables 
depending on the data type and its statistical distribution. 
Concentration-response relationships were constructed from single 
concentration experiments. The concentration-response relationships were 
quantified by fitting the data with the following biphasic equation: 
Y      =      Span x Fraction       +   Span x (1-Fraction)         
              (1 + ([D]/IC50_1)h1)           (1 + ([D]/IC50_2)h2) 
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Where Y is the magnitude of drug effect normalised as a percentage of the 
control effect; [D] is the concentration of drug; IC50_i is the drug 
concentration that produces half-maximal effect (50%) and h_i is an index 
of slope; for high affinity sites, i=1, and for low affinity sites, i=2. Span is 
the range of the drug effect (Maximum - minimum) and Fraction is the 
relative proportion of the concentration relationship described by the high 
affinity component. For the situation where only a monophasic, low 
affinity, relationship was observed, Fraction was set to zero. The IC50 
values are quoted with 95% confidence intervals. When data was best 
described by a monophasic relationship, the EC50 of the effect is equal to 
the IC50, however, when the data was best described by a biphasic 
relationship the EC50 of the effect was measured empirically. 
These procedures were all performed using PRISM 6 (GraphPad Software 
Inc., San Diego, CA). Statistical significance is defined as P <0.05, and is 
indicated in the figures as *** for p<0.001, ** for p<0.01 and * for 
p<0.05. 
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FIG. 1. Concentration-effect relationships for the effect of chlorpromazine (CPZ), 
haloperidol (HAL), risperidone (RIS) and clozapine (CLZ) on the reduction of MTT 
and exclusion of trypan blue (TBE). Data is measured at 4 different time points 
(, 4 hr; , 24hr; , 48hr and , 72hr), and is corrected for vehicle and 
background. The lines are all best fits of equation 1 to the data with IC50s given 
in figure 2. Data shown as means ± S.E.M (n=9) for each time point.
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FIG. 2.  The effect of incubation time (exposure duration) on the IC50 values 
determined for the reduction of MTT (), uptake of trypan blue () and release 
of LDH (), for the four different antipsychotics as indicated. Data is shown as 
the best fit value (symbol) with 5-95% confidence intervals (bars) of equation 1 
to data like that shown in Figure 1. Note that CPZ and CLZ appear to be the most 
cytotoxic with the smallest values of IC50, whereas RIS and HAL appear to be the 
least cytotoxic. The 72hr time point for CPZ is excluded due to its value being 
ambiguous: a pIC50 < 8.  
 
 
 
 
 
34 
 
 
  
FIG. 3. Time courses of HBMEC viability measured with three different assays for 
the four APs all at 10µM. The least viability was demonstrated with the MTT 
assay (), followed by LDH () and trypan blue exclusion (). Data are shown 
as means (± S.E.M; n=9). Note inflated Y-scale. 
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 FIG.  4. Representative transmission electron microscopy images of HBMECs of 
BBB treated with antipsychotic at its EC50 concentration for cell viability or 
vehicle as indicated.  Control cell (Cont.) treated with vehicle (2.5 µl ml-1 
ethanol) appear to possess a normal nucleus and cytoplasm. Whereas cells 
treated with the drugs all demonstrate a degraded vacuolated cytoplasm (V in 
VLZ image), nuclear breakdown, increased electron density and chromatin 
condensation. Scale bar = 2 µm.  
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FI
G.  5. Tail parameters determined from the Comet test (alkaline method) for 
HBMECs of BBB after 24hr incubation with antipsychotics. Top panels, 
comparison of tail moment (left panel) and tail DNA (right panel) for the four 
antipsychotics indicated at their EC50 for viability. Note that only CPZ elicited DNA 
breakage. Lower panels, comparison of tail moment and tail DNA for CPZ at its 
EC50 for viability, in the presence and absence of 10mM glutathione (GSH). Note 
how 10mM glutathione protects against DNA breakage by CPZ. Also shown is the 
effect of the positive control for DNA brakeage, 25 µM H202 for 1hr. Statistical 
significance is all relative to vehicle control. Data is shown as means (± S.E.M; 
n=3).  
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 FIG. 6.  The effects of antipsychotics on the activities of caspase-3, -8 and -9 
measured in HBMECs of the BBB. Cells were incubated for 24hr at the viability 
EC50 for the APs indicated. Statistical significance is relative to vehicle. Values are 
means ± S.E.M (n=3).  
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FIG. 7.  Top panels: Permeation of Evans blue across endothelial monolayers 
relative to vehicle control after 72hr incubation at the viability EC50 (left) and half 
that value (right) for the APs indicated. Statistical significance is relative to 
vehicle control. Values are means ± S.E.M (n=5). Bottom two panels: The 
relationships between the effects of antipsychotics on the transendothelial 
potential difference (TEPD) and transendothelial electrical resistance (TEER) of 
HBMECs as a function of incubation time: Vehicle (), CLZ (), RIS (), HAL 
() and CPZ (). Cells were incubated at half the viability IC50 for the APs 
indicated. Both TEPD and TEER were positively correlated with time and were all 
significantly larger than vehicle. Values are means (± S.E.M; n=3).  
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FIG. 8.  Top panels: Production of ROS as indicated by DCFDA fluorescence after 
24hr incubation in APs at their lowest concentrations tested (<10µM, left) and at 
their EC50s for viability (right), ANTA is the response to 2µM Antimycin A, the 
positive control. With the exception of RIS, at the lowest concentrations tested 
the APs significantly increased ROS relative to vehicle control (p<0.001, ANOVA). 
At their EC50s the APs all significantly increased ROS relative to vehicle control 
(p<0.001, ANOVA). Note the ~ 4 fold increase in ROS production when the 
higher concentration of drugs was used. Values are means ± S.E.M (n=3-4). 
Bottom panels: MTT reduction in the absence and presence of 10mM GSH after 
24hr incubation at the lowest concentrations of AP tested (<10µM, left) and at 
their EC50s for viability (right). With the exception of CLZ at its lowest 
concentration, 10mM glutathione (GSH) significantly (p<0.05 in all cases, 
Unpaired t-test with and without GSH) reversed the decrease in MTT reduction 
produced by the APs at both their lowest and EC50 concentrations. Values are 
means (± S.E.M; n=9). 
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